HFrEF treatment

As of 2026-09-09, the scientific consensus on HFrEF treatment is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

Major professional bodies have published 4 guideline recommendations on HFrEF treatment. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/hfref-treatment.